

PROVIDER Update



Community
Health Plan
OF IMPERIAL VALLEY

MEDI-CAL



CONTRACTUAL | APRIL 1, 2026 | UPDATE 26-417m | 4 PAGES

Medication Trend Updates and Drug List/Formulary Changes – 2nd Quarter 2026

Review drug list and medication benefit changes, and medication safety issues

Stay up to date with information about:

- FDA seeks removal of suicide warnings on GLP-1 weight loss drugs
- Changes to the Medi-Cal drug benefits for the second quarter of 2026

FDA seeks removal of suicide warnings on GLP-1 weight loss drugs

The Food and Drug Administration (FDA) requested that manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) remove warnings related to suicidal ideation and behavior (SI/B) from product labeling.

The affected products include:

- Novo Nordisk's Saxenda® (liraglutide)
- Novo Nordisk's Wegovy® (semaglutide)
- Eli Lilly's Zepbound® (tirzepatide)

This request follows a comprehensive FDA review that found no increased risk of SI/B associated with GLP-1 RA use. A meta-analysis of 91 placebo-controlled trials involving 107,910 patients also showed no increased risk of psychiatric adverse events with GLP-1 medications.

Notably, GLP-1 RA products approved for the treatment of type 2 diabetes mellitus do not currently include SI/B risk information in their labeling. To ensure consistent messaging across all FDA-approved GLP-1 RA products, the FDA is requesting removal of this warning from the prescribing information for Saxenda®, Wegovy®, and Zepbound®.

Healthcare professionals should be prepared to inform patients that, based on a comprehensive review of available data, the FDA has found no increased risk of suicidal ideation or behavior associated with these medications.

THIS UPDATE APPLIES TO:

- Physicians and Practitioners
- Participating Physician Groups

PROVIDER SERVICES

CHPIV Medi-Cal
(including ECM and CS providers) –
833-236-4141

PROVIDER PORTAL

provider.healthnetcalifornia.com

Community Health Plan of Imperial Valley ("CHPIV") is the Local Health Authority (LHA) in Imperial County, providing services to Medi-Cal enrollees in Imperial County. CHPIV contracts with Health Net Community Solutions, Inc. to arrange healthcare services for CHPIV enrollees. *Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Source: FDA news release at https://bit.ly/FDA_Removal_GLP-1_WeightLossDrug

Changes to Medi-Cal medication benefits

The Pharmacy Advisory Committee is made up of practicing physicians, pharmacists and other health care professionals. Every quarter, the committee reviews medication benefits for Medi-Cal members. They decide which medications stay on the same tier and which ones move to a different tier.

A table showing some of the recent changes for **Q2 2026** is available on **pages 3-4**. It includes:

- Medication names
- Their updated formulary status
- Formulary alternative options
- Notes or comments

You can find the complete list of formularies for all products, including for Medi-Cal on the Pharmacy Information for Providers page at <https://bit.ly/PharmacyInformationforProviders>.

For medical drug benefits, refer to the *Outpatient Pharmaceuticals (Submitted Under Medical Benefit)* section of the Community Health Plan of Imperial Valley Medi-Cal Fee-for-Service **Prior Authorization List** at <https://bit.ly/HealthNetPriorAuthorizations>.

Pharmacy help lines

For more information regarding changes to the Medi-Cal drug list or medication benefit, contact the proper pharmacy phone number listed.

Product	Phone number	Fax number
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-867-6564, option #2	833-953-3436

Need help? Contact us

If you have questions regarding the information contained in this update, contact Community Health Plan of Imperial Valley at 833-236-4141.

Changes to the Medi-Cal medication benefits

Note: The information in the tables is subject to change. For the most current details, please refer to the Prior Authorization List at <https://bit.ly/HealthNetPriorAuthorizations>.

Medication	Status	Formulary alternative(s)	Comments
Nasal preparation			
Cardamyst™ (etripamil) nasal spray	Carved out to state	Carved out to state	A calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults
Oral preparation			
Hyrnuo® (sevabertinib) tablet	Carved out to state	Carved out to state	A kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy
Komzifti™ (ziftomenib) capsule	Carved out to state	Carved out to state	A menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options
Kygewi™ (doxecitine and doxribtimine) powder for oral solution	Carved out to state	Carved out to state	A combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years
Lynkuet® (elinzanetant) capsule	Carved out to state	Carved out to state	A neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause
Myqorzo® (aficamten) film-coated tablet	Carved out to state	Carved out to state	A cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms

Changes to the Medi-Cal medication benefits, *continued*

Medication	Status	Formulary alternative(s)	Comments
Injectable preparation			
Exdensur® (depemokimab-ulaa) single-dose prefilled syringe/pen	Medical benefit ¹	Carved out to state	An interleukin-5 (IL-5) antagonist, a monoclonal antibody (humanized immunoglobulin G [IgG]1 kappa) indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older
Lerochol™ (lerodalcibep-liga) single-dose prefilled syringe	Medical benefit ¹	Carved out to state	A proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)
Waskyra™ (etuvetidigene autotemcel) suspension for intravenous use	Medical benefit ¹	Carved out to state	An autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients aged six months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available

¹Prior authorization is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.